Rhythm Pharmaceuticals, Inc.RYTM
Key ratios
FCF / Sales
-44.3%TTM
2025
-61.5%2024
-87.5%2023
-175.9%
Net margin
-85.6%TTM
2025
-103.6%2024
-200.3%2023
-238.5%
ROA
-27.5%2025
2024
-29.8%2023
-32.2%
ROE
-90.5%2025
2024
-155.9%2023
-85.1%
Revenue growth
53.5%TTM
2025
45.8%2024
68.1%2023
227.6%
Recent news
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE for Acquired Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Track RYTM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer